Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA approves Merck KGaA's Pimjetmi (pimicotinib) targeting CSF-1R for tenosynovial giant cell tumour following Ph3 data
Small molecule, cancer, CSF-1R inhibitor, tenosynovial giant cell tumour, rare disease - Read more

Start Center for Cancer Research, IFO partner to open early-phase oncology trial site in Italy
Research collaboration, oncology, early-phase trials, clinical trial site - Read more

BioNTech acquires Scholar Rock's FDA priority review voucher for $205M to accelerate oncology pipeline
Priority review voucher, oncology, bispecific antibody, antibody-drug conjugate, co-development - Read more

PharmaLogic acquires Lantheus' CDMO business and New Jersey plant for undisclosed sum
Acquisition, radiopharmaceuticals, manufacturing, CDMO, theranostics - Read more

Vor Bio licenses RemeGen's RC298 long-acting BAFF/APRIL inhibitor for $10M upfront, $346M total
Licensing deal, autoimmune, biologics, milestone payments, equity investment - Read more

Pfizer secures $1.5B financing from Blackstone Life Sciences to fund obesity drug berobenatide development through 2028
Equity investment, obesity, small molecule, milestone payments, commercialization - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Amgen shares Ph3 data for (dazodalibep) targeting CD40L in systemic Sjögren's disease, showing strong ESSDAI improvements
Protein therapy, autoimmune, fusion protein, Sjögren's disease, CD40L antagonist - Read more

Beeline Medicines' (afimetoran) Ph2 data show 30-point advantage over placebo in systemic lupus erythematosus
Small molecule, autoimmune, TLR7/8 inhibitor, systemic lupus erythematosus, corticosteroid-sparing - Read more

Lundbeck raises full-year revenue and earnings forecasts after Vyepti-driven Q3 beat
Monoclonal antibody, neurological, revenue impact, financial - Read more

Neurosterix raises $105M Series B to advance oral schizophrenia candidate into mid-stage trials
Neuropsychiatric, small molecule, schizophrenia, allosteric modulator, clinical-stage - Read more

VectorY Therapeutics raises €74.5M ($83.5M) in new financing to advance neurodegenerative gene-delivered antibody pipeline
Gene therapy, neurological, antibody, ALS, neurodegenerative, clinical-stage - Read more

Eli Radiopharma raises $60M Series A to advance radiopharmaceutical assets into clinical development
Radiopharmaceuticals, oncology, neurological, preclinical, diagnostics - Read more

Cancer Research UK launches £8M ($10.6M) AI co-scientist project to accelerate cancer research discoveries
Agentic AI, oncology, operational, investment - Read more

Valo Health merges with Montai Therapeutics under Valo brand to advance AI-driven drug pipeline
AI drug discovery, oncology, autoimmune, major transaction - Read more

Sandoz launches Ranluspec ranibizumab biosimilar in Europe for affordable retinal disease treatment
Biosimilar, ophthalmology, strategic, competitive - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Legend Biotech shares drop 16% after cautious Carvykti 2027 sales outlook overshadows Q3 profit
CAR-T, oncology, financial, competitive - Read more

Capricor Therapeutics cuts 10% of workforce as FDA decision on DMD cell therapy deramiocel approaches
Cell therapy, rare disease, regulatory, cost reduction - Read more

Harvard analysis warns US pressure to raise German drug prices would increase costs in both countries
Drug pricing policy, pharmaceutical industry, financial, regulatory, competitive - Read more

Eugia, unit of Aurobindo, recalls vancomycin antibiotic lot over glass particle contamination concerns
Small molecule, infectious disease, operational, safety recall - Read more

FDA quietly pauses controversial Commissioner's National Priority Voucher speedy drug review pilot program
FDA review program, small molecule, regulatory, operational - Read more

FDA warns Chongqing Qiancan Technology, Tianjin Healthcare Medical Technology over record-request refusals, issues import alerts
API manufacturing, compounding, regulatory, operational - Read more

Kyverna drops next-gen KYV-102 CAR-T program to focus on miv-cel autoimmune approval
CAR-T, autoimmune, strategic, pipeline - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here